¼îÐÔ³ÉÏËάϸ°ûÉú³¤Òò×Ó£¨bFGF£©£¬ÊôÓÚ³ÉÏËάϸ°ûÉú³¤Òò×Ó¼Ò×壬ͨ¹ý½áºÏ²¢¼¤»î°Ðϸ°û±íÃæµÄÊÜÌå´¥·¢Ò»ÏµÁÐÐźÅתµ¼Í¨Â·¡£bFGF ¿ÉÒÔÓ°Ïì¶àÖÖϸ°ûµÄÔöÖ³£¬°üÀ¨ÄÚÆ¤Ï¸°û¡¢Éñ¾Ôª¡¢Èí¹Çϸ°û¡¢Æ½»¬¼¡Ï¸°û¡¢ºÚËØÏ¸°ûºÍÖ¬·¾Ï¸°û¡£´ËÍ⣬bFGF²ÎÓë¸÷ÖÖÉúÎï¹ý³Ì£¬°üÀ¨Ï¸°ûµÄ×ÔÎÒ¸üС¢·Ö»¯¡¢·¢Óý¡¢×éÖ¯ÐÞ¸´ºÍÔÙÉú¡£×÷Ϊϸ°ûÉú³¤µÄ¹Ø¼üÒò×Ó£¬bFGF±»¹ã·ºÓ¦ÓÃÓÚ¶àÖÖϸ°ûµÄÌåÍâÅàÑø¡£
Ñо¿±íÃ÷£¬bFGFÔÚÉúÀíÌõ¼þϲ»Îȶ¨£¬ÔÚ²¸È鶯Îïϸ°ûÅàÑøÌõ¼þϵİëË¥ÆÚԼΪ8Сʱ¡£ÓÉbFGFµÍÈÈÎȶ¨ÐÔÓë½Ï¶Ì°ëË¥ÆÚµ¼ÖÂϸ°ûÉú³¤³öÏÖµÄÎÊÌ⣬ÐèҪͨ¹ýÔÚÅàÑø¹ý³ÌÖв¹³äÉú³¤Òò×Ó£¬»òÕßÿÌì¸ü»»ÅàÑø»ùÀ´½â¾ö¡£ÔÚÌìÈ»bFGF»ù´¡ÉϸÄÁ¼µÃµ½µÄbFGFµ°°×£¨ÄÍÈÈÐÍ£©½â¾öÁËÕâÒ»ÄÑÌâ¡£ËüÔÚ±£ÁôÁËÌìÈ»bFGFÇ¿´óÉúÎïѧ»îÐÔµÄͬʱ£¬ÏÔÖøÌáÉýÁËÈÈÎȶ¨ÐÔ£¬¿ÉÄÍÊܸü¸ßζȣ¬ÔÚ½ÏΪ¿í·ºµÄζÈÇø¼äÄÚ±£³Ö·Ö×ӽṹ¡¢Î¬³Öµ°°×»îÐÔ¡£
ÈËÅßÌ¥¸Éϸ°û£¨hESC£©ºÍÓÕµ¼ÐÔ¶àÄܸÉϸ°û£¨iPSC£©¾ßÓзֻ¯ÎªËùÓÐÌåϸ°ûÀàÐ͵ÄDZÄÜ¡£ÔÚÌåÍâÅàÑøhESCºÍiPSCµÄ¹ý³ÌÖУ¬bFGF¶ÔÓÚά³Ö¸Éϸ°ûµÄ¶àÄÜÐԱز»¿ÉÉÙ¡£Ñо¿·¢ÏÖ£¬Ìí¼ÓbFGFµ°°×£¨ÄÍÈÈÐÍ£©ÅàÑøµÄhESCÄܹ»ÒÔ¸ü¿ìµÄËÙ¶ÈÐγÉδ·Ö»¯µÄϸ°û¿Ë¡£¨Í¼1A£©£¬ÇÒÔÚ³¤ÆÚÅàÑøÄǸö¹ý³ÌÖÐÌá¸ßÁËϸ°ûµÄÔöÖ³ËÙ¶È£¨Í¼1B£©¡£ÉîÈëÑо¿·¢ÏÖ£¬bFGFµ°°×£¨ÄÍÈÈÐÍ£©Äܹ»ÔÚ»ý¼«Ó°ÏìhESCÔöÖ³ËٶȵÄͬʱ£¬Î¬³Ö¶àOCT4¡¢SOX2¡¢KLF4µÈ¶àÖÖ¸ÉÐÔ±ê¼ÇÎïµÄ±í´ï£¬ËµÃ÷ÆäÄܹ»±£³ÖhESCµÄ¶àÄÜÐÔ£¬Õâ¶ÔbFGFµ°°×£¨ÄÍÈÈÐÍ£©ÔÚϸ°ûÅàÑøÁìÓòµÄÓ¦ÓÃÖÁ¹ØÖØÒª¡£
ͼ1 bFGFµ°°×ÄÍÈÈÐÍÓëÒ°ÉúÐͶÔhESCϸ°ûÔöÖ³µÄÓ°Ï죨DOI: 10.3390/biology12060888£©
A£ºÎÞËÇÑø²ãÅàÑøÌõ¼þÏ£¬Ê¹Óò»Í¬ÀàÐÍbFGFµ°°×ʱ£¬hESCµÚ2ÌìµÄÉú³¤Çé¿ö¡£B£ºÎÞËÇÑø²ãÅàÑøÌõ¼þÏ£¬Ê¹Óò»Í¬ÀàÐÍbFGFµ°°×Á¬ÐøÅàÑø£¬Ï¸°ûÉú³¤ÂʵıȽϡ£WT-bFGF£ºbFGFµ°°×Ò°ÉúÐÍ¡£TS-bFGF£ºbFGFµ°°×ÄÍÈÈÐÍ¡£
¾º¼¼±¦¹ÙÍøÍÆ³ö£ºÖØ×éÈËbFGFµ°°×£¨ÄÍÈÈÐÍ£©
²úÆ·ÌØµã£ºÄÍÈÈÐԺᢸߴ¿¶È¡¢¸ß»îÐÔ¡¢µÍÄÚ¶¾ËØ¡¢ÎÞ¾ú¡¢ÎÞÖ§ÔÌå¡£
²úÆ·ÐÔÄÜ£º
ͼ2 ÔÚ»¹ÔÌõ¼þÏ£¬ÖØ×éÈËbFGFµ°°×ÄÍÈÈÐ͵ÄSDS-PAGE´¿¶È´óÓÚ90%
ͼ3 ½«100ng/mLµÄ¾ºÆ·ºÍT&L²úÆ··Ö±ð·ÅÖÁ37¡æ£¬72Сʱºó½øÐлîÐÔ¼ì²â£¬T&L²úÆ·»îÐÔΪ¾ºÆ·µÄ6±¶×óÓÒ¡£
ͼ4 ½«100ng/mLµÄ¾ºÆ·ºÍT&L²úÆ··Ö±ð·Åµ½-80¡æ¡¢4¡æºÍ37¡æ£¬72Сʱºó½øÐлîÐÔ¼ì²â¡£¾ºÆ·µÄ»îÐÔËæ×Å·ÅÖÃζÈÉý¸ßÖð½¥½µµÍ£¬¶øT&L²úÆ·ÔÚ²»Í¬·ÅÖÃζÈÏ£¬»îÐÔÎÞÃ÷ÏԱ仯¡£
Ìí¼ÓÔÚiPSCÅàÑø»ùÖУ¬¿Éÿ2Ìì»»ÒºÒ»´Î¡£
Èçͼ5Ëùʾ£¬·Ö±ð½«¾º¼¼±¦¹ÙÍøÖØ×éÈËbFGFµ°°×£¨GMP-TL901£©¡¢ÖØ×éÈËbFGFµ°°×£¨ÄÍÈÈÐÍ£©Ó¦Óõ½AMMS?¶àÄܸÉϸ°ûÅàÑø»ù£¨AS-35£©ÖÐÅàÑøiPSC¡£Ìí¼ÓbFGFµ°°×£¨ÄÍÈÈÐÍ£©µÄÅàÑø»ùÖУ¬Ã¿Ìì»»Òº»ò¸ôÌì»»Òº×飬ϸ°ûµÄ¿Ë¡ÊýÄ¿¡¢¿Ë¡ÍÅ´óСÏà½ÏÌí¼ÓÆÕͨÐ͵°°××é¾ùÓÐÃ÷ÏÔÌáÉý¡£È»¶ø£¬Ìí¼ÓÄÍÈÈÐ͵°°×ºó£¬¸ôÌì»»ÒºÓëÿÌì»»ÒºµÄ·½°¸Ö®¼äϸ°û״̬Ïà²î²»´ó¡£Òò´Ë£¬¾º¼¼±¦¹ÙÍøµÄbFGFµ°°×£¨ÄÍÈÈÐÍ£©¿ÉÒÔÊÊÅäiPSC¸ôÌì»»ÒºµÄÅàÑø·½°¸¡£
ͼ5 ½«bFGFµ°°×ÆÕͨÐÍ»òÄÍÈÈÐÍÌí¼Óµ½iPSCÅàÑøÌåϵÖУ¬²»Í¬ÅàÑø·½°¸¶ÔiPSCϸ°û¿Ë¡ÍÅÐγɵÄÓ°Ïì±È½Ï¡£
²Î¿¼ÎÄÏ×
[1] Dvorak P, Bednar D, Vanacek P, Balek L, Eiselleova L, Stepankova V, Sebestova E, Kunova Bosakova M, Konecna Z, Mazurenko S, Kunka A, Vanova T, Zoufalova K, Chaloupkova R, Brezovsky J, Krejci P, Prokop Z, Dvorak P, Damborsky J. Computer-assisted engineering of hyperstable fibroblast growth factor 2. Biotechnol Bioeng. 2018 Apr;115(4):850-862. doi: 10.1002/bit.26531. Epub 2018 Jan 24. PMID: 29278409.
[2] Kim S, Kang GH, Lim KM, Shin Y, Song K, Park S, An J, Kim DY, Shin HC, Cho SG. Thermostable Human Basic Fibroblast Growth Factor (TS-bFGF) Engineered with a Disulfide Bond Demonstrates Superior Culture Outcomes in Human Pluripotent Stem Cell. Biology (Basel). 2023 Jun 20;12(6):888. doi: 10.3390/biology12060888. PMID: 37372172; PMCID: PMC10294964.
[3] Lyra-Leite DM, Fonoudi H, Gharib M, Burridge PW. An updated protocol for the cost-effective and weekend-free culture of human induced pluripotent stem cells. STAR Protoc. 2021 Feb 3;2(1):100213. doi: 10.1016/j.xpro.2020.100213. PMID: 33786455; PMCID: PMC7988236.
[4] Benington L, Rajan G, Locher C, Lim LY. Fibroblast Growth Factor 2-A Review of Stabilisation Approaches for Clinical Applications. Pharmaceutics. 2020 Jun 2;12(6):508. doi: 10.3390/pharmaceutics12060508. PMID: 32498439; PMCID: PMC7356611
¹ØÓÚ¾º¼¼±¦¹ÙÍøÉúÎ
±±¾©¾º¼¼±¦¹ÙÍøÉúÎï¿Æ¼¼ÓÐÏÞ¹«Ë¾£¬×¨×¢Ï¸°ûºÍ»ùÒòÖÎÁÆ£¨CGT£©GMP¼¶ÔÁÏÊÔ¼ÁÑз¢¼°Éú²ú£¬ÎªCGTÓû§Ìṩ²úÆ·Óë·þÎñµÄÕûÌå½â¾ö·½°¸¡£²úÆ·Éæ¼°Ï¸°û·ÖÑ¡´ÅÖéÊÔ¼Á¡¢ÖØ×éÈËÔ´µ°°×¡¢ÎÞѪÇåÅàÑø»ù¡¢Ï¸°ûÅàÑøÊÔ¼ÁºÐµÈ¡£¹«Ë¾½¨ÓÐ3200m2µÄÑз¢ÊµÑéÊÒ¼°GMP¼¶½à¾»³µ¼ä£¬°üÀ¨Ï¸°û·ÖÑ¡´ÅÖ鿪·¢Æ½Ì¨¡¢ÕæºËÓëԺ˵°°×±í´ï¹¤³Ìƽ̨¡¢ÎÞѪÇåÅàÑø»ù¿ª·¢Æ½Ì¨£¬Í¨¹ýISO13485ºÍISO9001Ë«ÖÊÁ¿ÌåϵÈÏÖ¤£¬²¿·Ö²úÆ·ÒÑ»ñÃÀ¹úFDA DMF±¸°¸¡£
ÖÜÒ» ÖÁ ÖÜÎå
09:00-17:30
רҵɨÂë»ñÈ¡
רҵ×Éѯ·þÎñ